Table 1.
Diagnostic and management details of the IPF cohort
| Variables N(%) or mean ± SD | Obese, BMI ≥30 kg/m2 (n = 49, 35.5%) | Nonobese, BMI <30 kg/m2 (n = 89, 64.5%) | All IPF cohort (n = 138) | P |
|---|---|---|---|---|
|
| ||||
| Diagnostics | ||||
| 1. HRCT patterns | ||||
| UIP | 34 (69.4) | 76(85.4) | 110(79.7) | 0.007 |
| Probable LIP | 15(30.6) | 13(14.6) | 28 (20.3) | |
| 2. Lung biopsy | 14(28.6) | 9(10.1) | 24(17.4) | 0.001 |
| 3. Seen at tertiary or ILD center | 32 (65.3) | 40 (44.9) | 72 (52.2) | 0.004 |
| 4a. Incident diagnosis (within 6 mo) | 23 (46.9) | 34 (38.2) | 57 (41.3) | 0.021 |
| 4b. Prcsalcnt diagnosis | 27(51) | 54 (60.7) | 81 (58.6) | 0.200 |
| Years since diagnosis | 4.11 ±3.03 | 4.17 ± 3.04 | 4.15 ±3.02 | 0.461 |
| PFT at diagnosis | ||||
| FEV1% predicted | 81.31 ± 14.68 | 78.63 ± 20.01 | 79.74 ± 17.98 | 0.231 |
| FVC% predicted | 75.24 ± 15.60 | 70.47 ± 19.88 | 72.43 ± 18.31 | 0.098 |
| DLCO% predicted | 45.83 ± 17.31 | 45.73 ± 16.88 | 45.77 ± 16.96 | 0.488 |
| 6MWD, m | 253.2 ± 142.57 | 257.64 ± 124.86 | 255.82 ± 13126 | 0.449 |
| Management | ||||
| Supplemental O2 prescribed | 40(81.6) | 69 (77.5) | 109 (79) | 0.381 |
| Supplemental O2 l/min | 2.74 ± 1.91 | 2.62 ± 1.95 | 2.67 ± 1.93 | 0.369 |
| Antifibrotics | ||||
| Nintcdanib | 12(24.5) | 18(20.2) | 30 (21.7) | 0.397 |
| Pirfcnidonc | 12(24.5) | 18(20.2) | 30 (21.7) | 0.397 |
| Lung transplant | 5 00.2) | 0 | 5 (3.6) | |
| Mortality | 10(20.4) | 31 (34.8) | 41 (29.7) | 0.01H |
| Lndcrwcight (BMI <20) 6 (19.4%) | <0.001 | |||
| Normal (BMI 20–24.9) 15 (48.3%) | ||||
| Overweight (BMI 25–29.9) 10 (32.3%) | ||||
Italicized/bold P values refers to significant P values.
6MWD, 6-minute walk distance; BMI, body mass index; DLCO, diffusion capacity for carbon monoxide; FFV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HRCT, high-resolution computer tomography: ILD; interstitial lung disease; IPF, idiopathic pulmonary fibrosis; PFT, pulmonary function test; SD, standard deviation; VIP: usual interstitial pneumonia.